热景生物业绩快报：2024年净利润亏损1.79亿元

Core Viewpoint - The company reported a decline in revenue and a significant net loss for the year 2024, indicating challenges in its financial performance [1] Financial Performance - The total operating revenue for 2024 was 511 million yuan, representing a year-on-year decrease of 7.62% [1] - The net profit for the year was a loss of 179 million yuan, compared to a net profit of 28.52 million yuan in the same period last year [1] Research and Development - The company continued to invest in research and development for clinical immunodiagnostics and molecular diagnostics technology platforms [1] - The total R&D expenditure amounted to 113 million yuan, accounting for 22.07% of the operating revenue [1]